Anzeige
Erschienen in:
01.01.2009 | Adis Drug Profile
Ropinirole Prolonged Release
In Advanced Parkinson’s Disease
Erschienen in: CNS Drugs | Ausgabe 1/2009
Einloggen, um Zugang zu erhaltenAbstract
▴ Ropinirole prolonged release is a non-ergoline dopamine receptor agonist that is indicated for the treatment of Parkinson’s disease.
▴ Once-daily ropinirole prolonged release and threetimes-daily ropinirole immediate release have similar exposure over 24 hours. The prolonged-release formulation is associated with fewer fluctuations in plasma ropinirole concentrations.
▴ Two well designed, placebo- or active comparatorcontrolled trials examined the efficacy of ropinirole prolonged release in patients with advanced Parkinson’s disease suboptimally controlled by levodopa. In the placebo-controlled trial, 24 weeks’ therapy with ropinirole prolonged release 6–24 mg once daily reduced hours of ‘off’ time (primary endpoint) to a significantly greater extent than placebo. In the active comparator-controlled trial, significantly more ropinirole prolonged-release recipients than ropinirole immediate-release recipients maintained a ≥20% reduction from baseline in ‘off’ time at week 24 (primary endpoint).
▴ Ropinirole prolonged release 6–24 mg once daily was generally well tolerated in patients with advanced Parkinson’s disease; adverse events were generally typical of non-ergoline dopamine receptor agonists.